Prevalence and Trends of Opioid Use in Patients With Depression in the United States

Terence Tumenta¹, Derek F. Ugwendum², Muchi Ditah Chobufo³, Etaluka Blanche Mungu⁴, Irina Kogan¹, Tolulope Olupona¹

1. Psychiatry, Interfaith Medical Center, Brooklyn, USA 2. Public Health (Alumni), George Washington University, Washington, USA 3. Internal Medicine, Interfaith Medical Center, Brooklyn, USA 4. Preventive Medicine, Gerald Family Care, Washington, USA

Corresponding author: Terence Tumenta, tshendeh@gmail.com

Abstract

Background

Depression and prescription opioid use have a bi-directional relationship. Depression commonly co-occurs with chronic noncancer pain and is known to be associated with opioid use. Studies have found an increased risk of depression only in patients with opioid dependence. Other studies have found an increased risk of opioid misuse in depressed patients. In addition, chronic pain conditions can lead to depression without the use of opioids.

Methods

We used the National Health and Nutrition Examination Survey (NHANES) data collected over seven survey cycles spanning 14 years: 2005/2006-2017/2018. Included in our study were participants ≥18 years who completed the patient health (PHQ-9) questionnaire. Persons with documented use of opioids were considered to have chronic use of opioids. Relevant data files were merged, and analytical weights computed in keeping with the survey analytical guidelines. Prevalence measures are reported as proportions. Associations were assessed using the Chi-square test. Binary logistic regression was used to assess the trend in the prevalence of opioid use. We used STATA-16 for data analysis and p-values <0.05 were considered statistically significant.

Results

A total of 36,459 participants met the inclusion criteria. The prevalence of depression was 7.7% (95% CI: 7.3-8.2). The prevalence of any narcotic use was 6.0%. Among depressed individuals, Blacks: OR 0.71 (95% CI: 0.54-0.93) and Hispanics: OR 0.48 (95% CI: 0.34-0.67) were less likely to be on narcotics compared to non-Hispanic Whites. The prevalence of opioid use was stable over the first 12 years, followed by a significant drop in the last two years.

Conclusion

Beyond the risk for opioid misuse, and opioid use disorder, depression should also be considered when prescribing opioids. It is therefore important to implement a training to screen for depression in patients receiving opioids for pain management.

Categories: Pain Management, Psychiatry, Public Health

Keywords: opioid use, prevalence, trend, depression, public health

Introduction

In 1800s, the medicinal properties of opiates were recognized and were used by physicians to effectively alleviate suffering in patients. They were also used to treat cough, diarrhea, anxiety and minor pains [1,2]. Over the years, opioid use in the United States has been a public health crisis which still continues to escalate [3-6]. In the past two decades, the prescription of opioid analgesic has increased [7-9]. In 2012, 259 million adults living in the United States had a prescription written order for opioid pain reliever [10]. This has posed a significant burden on the US health care system as the rate of opioid use disorders and opioid-related deaths have increased due to its increased use [11-13]. Opioid-related hospitalization increased between 2005 and 2014 accounting for 225 hospitalizations per 100,000 populations [3]. Death rate from opioid overdose increased to 27% from 2015 to 2016 [6].

Depression commonly co-occurs with chronic noncancer pain and is known to be associated with opioid use [14]. Some studies have found an increased risk of depression only in patients with opioid dependence [14]. Others have shown an increased risk of opioid misuse in patients with depression [15]. Also, chronic pain conditions can cause depression independent of opioid use [15]. Depression and prescription opioid use

Review began 05/22/2021

Review ended 05/23/2021

Published 05/28/2021

© Copyright 2021

Tumenta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Tumenta T, Ugwendum D F, Chobufo M, et al. (May 28, 2021) Prevalence and Trends of Opioid Use in Patients With Depression in the United States. Cureus 13(5): e15309. DOI 10.7759/cureus.15309

have a bi-directional relationship [15-17]. Depression is a well-established risk factor for receiving a prescription opioid for non-cancer pain, receiving opioids at higher doses and for longer duration, as well as elevating risk for both opioid misuse and opioid use disorder [14,16-21].

The main objective of this study is to explore the relationship between opioid use and depression, while describing the prevalence of opioid use in people with depression in the United States. The secondary objective is to measure the trend of opioid use in patients with depression.

Materials And Methods

Survey design

The National Health and Nutrition Examination Survey (NHANES) conducted by the National Center for Health Statistics (NCHS), is a nationally representative survey on the health and nutrition status of non-institutionalized US population. The survey utilizes a multistage probability sampling design to collect information from approximately 5,000 persons in 15 counties yearly. Details of the survey design and data collection have been previously published [22]. We utilized data collected over seven survey cycles spanning 14 years: 2005/2006-2017/2018. Ethical clearance was approved by the NCHS Research Ethics Review Board [22].

Data collection

Participants were interviewed at their homes to ascertain demographic characteristics. The interviewers were followed by the administration of the patient health questionnaire (PHQ-9) at mobile examination centers (MEC) to eligible participants. Included in our study were participants ≥ 18 years who completed the PHQ-9 questionnaire. Because of the sensitive nature of the questions, PHQ-9 questionnaires were not administered to participants needing proxies for completion. The PHQ-9 has been validated as an accurate screening tool for depression with scores ≥ 10 having a sensitivity and specificity of 88% across different study populations for the diagnosis of depression [22]. Prescription medication use is assessed by interviewers with visual confirmation using prescription packages. List of all medications considered as narcotics are listed in the appendix. Persons with documented use of opioids were considered to have chronic use of opioids. Persons who reported having smoked ≥ 100 cigarettes in their lifetimes were classified as smokers. The family poverty index ratio (PIR) was computed by dividing the total family income by the poverty threshold income, adjusting for family size. All study questionnaires, response options, and complete data, are publicly available.

Statistical analysis

Relevant data files were merged, and analytical weights computed following the survey analytical guidelines. Included in our analysis were participants ≥ 18 years with completed PHQ-9 questionnaires. Prevalence measures are reported as proportions. Associations were assessed using the Chi-square test. Binary logistic regression was used to assess the trend in prevalence of opioid use and graphically represented using a local polynomial smoothed line with 95% CI. We used STATA-16 for data analysis and p-values < 0.05 were considered statistically significant.

Results

In all, 36,459 met the inclusion criteria. The prevalence of depression in our study was 7.7% (95% CI: 7.3-8.2). Blacks: OR 1.3 (95% CI: 1.2-1.5) and Hispanics: OR 1.2 (95% CI 1.1-1.4) were more likely to be depressed compared to non-Hispanic Whites. The prevalence of any narcotic use was 6.0% in the general population and 17.2% in those with depression (see Table 1). Hispanics were less likely to use narcotics compared to non-Hispanic Whites and non-Hispanic Blacks. Among depressed individuals, Blacks: OR 0.71 (95% CI: 0.54-0.93) and Hispanics: OR 0.48 (95% CI: 0.34-0.67) were less likely to be on narcotics compared to non-Hispanic Whites.

Variable	Categories	General population	Depressed	Not depressed
Age (years)		46.5	46.2	46.6
Body mass index (kg/m ²)		29.0	30.6	28.8
Gender (%)	Male	48.8	36.2	49.9
	Female	51.2	63.8	50.1
Ethnicity (%)	NH White	67.5	63.1	67.8
	Hispanic	14.1	16.1	13.9
	NH Black	11.2	13.6	11.0
	Others	7.3	7.2	7.3
Educational status (%)	< High school	5.1	8.6	4.9
	High school or GED	10.5	17.0	9.9
	College	84.4	74.4	85.2
Marital status (%)	Married	63.3	47.6	64.6
	Divorced	18.5	31.1	17.4
	Never married	18.2	21.2	18.0
Country of birth (%)	USA	83.5	86.2	83.3
	Non-USA	16.5	13.8	16.7
Insurance (%)	Yes	82.5	76.3	83.0
Current smoker (%)	Yes	19.7	38.6	18.1
Ever smoker (%)	Yes	43.9	60.2	42.5
Poverty index ratio (%)	<1	13.4	27.6	12.2
	1-3	33.4	41.0	32.7
	>3	53.3	31.4	55.1
Narcotics use (%)	Yes	6.0	17.2	5.0
	No	94.0	82.8	95.0

TABLE 1: General characteristics of the study population.

NH: non-Hispanic.

The prevalence of opioid use was stable over the first 12 years, followed by a significant drop in the last two years (see Table 2).

Period	Prevalence of opioid use	P _{delta}	P _{trend}
2005-2008 (N=835)	18.5 (14.8-25.2)	-	0.069
2009-2012 (N=968)	17.8 (14.2-22.2)	0.812	
2013-2016 (N=940)	19.1 (14.5-24.9)	0.848	
2017-2018 (N=461)	10.7 (7.2-15.6)	0.015	

TABLE 2: Trends in prevalence of opioid use among patients with depression.

Discussion

We looked at the prevalence of opioid use in patients with depression, using NHANES survey data. Responders with depression were more than three times more likely to be using opioids than those who were not depressed. Our study contributes to the growing literature on opioid use and risk of depression. It emphasizes that beyond the risk for opioid misuse, and opioid use disorder, depression should also be considered when prescribing opioids.

There appears to be a link between opioid use and depression, but the direction is uncertain given the cross-sectional nature of the NHANES survey. However, our findings are in keeping with other literature, suggesting that there is risk of new-onset or worsening depression with opioid use [14,15-21]. This increased risk is seen in both males and females [18].

There is an evidence to indicate that endogenous opioids have important roles in human mood and that endogenous mu and kappa opioid tone is dysregulated in the context of depression [23,24]. The underlying mechanisms of prescription opioids in the pathophysiology of depression are still unknown, but they may include opioid-induced dysregulation of reward circuitry, which results in decreased reward perception or pleasure and relief generation, or other physical medical dysregulation, which may contribute to the physical symptoms of depression. Studies have reported that prolonged opioid use (more than 30 days) contributes significantly to developing depression, even more than high doses of opioids [25-27].

Other studies have reported that the severity of depression is associated with increasing likelihood of misusing opioid medications for non-pain symptoms. Also, about one-third of patients who use long-term opioids and who have co-occurring depression, meet criteria for opioid use disorder. More than half of individuals with opioid use disorder have comorbid depression. This suggests that targeting opioid use prevention for patients with depression may help mitigate the US opioid epidemic [25].

There are some limitations to this study. The NHANES data is cross-sectional in nature, limiting its use for cause-effect analysis. Other limitations are related to the study design (survey), including recall bias, low response rate, and the fact that survey responders may not have provided accurate and honest answers to the questions. However, a strength of our study is that it represents the first to provide nationwide estimates of the prevalence of opioid use among patients with depression and using in person drug verifications to determine persons on narcotics allows for accurate determination of its use.

Conclusions

Our study found that among people who reported taking opioids, the number of people who were depressed was more than three times those who were not depressed. It is therefore important to implement a training to screen for depression in patients receiving opioids for pain management.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to acknowledge all the survey participants without whom this study would not have been feasible.

References

1. Courtwright DT: Preventing and treating narcotic addiction--century of federal drug control . *N Engl J Med*. 2015, 373:2095-7. [10.1056/NEJMp1508818](https://doi.org/10.1056/NEJMp1508818)
2. Trickey E. Inside the story of America's 19th-century opiate addiction . (2018). Accessed: April 25, 2021: <https://www.smithsonianmag.com/history/inside-story-americas-19th-century-opiate-addiction-180967673/>.
3. Weiss AJ, Bailey MK, O'Malley L, Barrett ML, Elixhauser A, Steiner CA: Patient Characteristics of Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2014. *Healthcare Cost and Utilization Project (HCUP) Statistical Briefs*. 2017, Statistical Brief #224:1-19.
4. Martins SS, Sampson L, Cerdá M, Galea S: Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. *Am J Public Health*. 2015, 105:e29-49. [10.2105/AJPH.2015.302843](https://doi.org/10.2105/AJPH.2015.302843)
5. Jones CM, Logan J, Gladden RM, Bohm MK: Vital signs: demographic and substance use trends among heroin users - United States, 2002-2013. *MMWR Morb Mortal Wkly Rep*. 2015, 64:719-25.
6. Seth P, Scholl L, Rudd RA, Bacon S: Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. *MMWR Morb Mortal Wkly Rep*. 2018, 67:349-58. [10.15585/mmwr.mm6712a1](https://doi.org/10.15585/mmwr.mm6712a1)
7. Atluri S, Sudarshan G, Manchikanti L: Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. *Pain Physician*. 2014, 17:e119-28.
8. Centers for Disease Control and Prevention (CDC): Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. *MMWR Morb Mortal Wkly Rep*. 2011, 60:1487-92.
9. Mojtabai R: National trends in long-term use of prescription opioids . *Pharmacoeconomic Drug Saf*. 2018, 27:526-34. [10.1002/pds.4278](https://doi.org/10.1002/pds.4278)
10. Paulozzi LJ, Mack KA, Hockenberry JM: Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC. Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012. *MMWR Morb Mortal Wkly Rep*. 2014, 63:563-8.
11. Bolash RB: Trends in opioid analgesic abuse and mortality in the United States . *N Engl J Med*. 2015, 372:1573. [10.1056/NEJMc1501822](https://doi.org/10.1056/NEJMc1501822)
12. Rudd RA, Seth P, David F, Scholl L: Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. *MMWR Morb Mortal Wkly Rep*. 2016, 65:1445-52. [10.15585/mmwr.mm65051e1](https://doi.org/10.15585/mmwr.mm65051e1)
13. Warner M, Hedegaard H, Chen LH. Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012. *NCHS health e-stats*. (2014). Accessed: December 2016: http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning_deaths_1999-2012.pdf.
14. Scherrer JF, Salas J, Copeland LA, et al.: Prescription opioid duration, dose, and increased risk of depression in 3 large patient populations. *Ann Fam Med*. 2016, 14:54-62. [10.1370/afm.1885](https://doi.org/10.1370/afm.1885)
15. Semenkovich K, Chockalingam R, Scherrer JF, et al.: Prescription opioid analgesics increase risk of major depression: new evidence, plausible neurobiological mechanisms and management to achieve depression prophylaxis. *Mo Med*. 2014, 111:148-54.
16. Zubatsky M, Witthaus M, Scherrer JF, Salas J, Gebauer S, Burge S, Schneider FD: The association between depression and type of treatments received for chronic low back pain. *Fam Pract*. 2020, 37:348-54. [10.1093/fampra/cmz062](https://doi.org/10.1093/fampra/cmz062)
17. Salas J, Miller MB, Scherrer JF, et al.: The association of opioid use duration and new depression episode among patients with and without insomnia. *J Opioid Manag*. 2020, 16:317-28. [10.5055/jom.2020.0587](https://doi.org/10.5055/jom.2020.0587)
18. Salas J, Scherrer JF, Ahmedani BK, et al.: Gender and the association between long-term prescription opioid use and new-onset depression. *J Pain*. 2018, 19:88-98. [10.1016/j.jpain.2017.09.004](https://doi.org/10.1016/j.jpain.2017.09.004)
19. Scherrer JF, Salas J, Schneider FD, et al.: Characteristics of new depression diagnoses in patients with and without prior chronic opioid use. *J Affect Disord*. 2017, 210:125-9. [10.1016/j.jad.2016.12.027](https://doi.org/10.1016/j.jad.2016.12.027)
20. Scherrer JF, Salas J, Copeland LA, et al.: Increased risk of depression recurrence after initiation of prescription opioids in noncancer pain patients. *J Pain*. 2016, 17:473-82. [10.1016/j.jpain.2015.12.012](https://doi.org/10.1016/j.jpain.2015.12.012)
21. Scherrer JF, Ahmedani B, Autio K, et al.: The prescription opioids and depression pathways cohort study . *J Psychiatr Brain Sci*. 2020, 5:10.20900/jpbs.20200009
22. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK: National health and nutrition examination survey: sample design, 2011-2014. *Vital Health Stat*. 2014, 162:1-33.
23. Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, Fava M: Evaluation of opioid modulation in major depressive disorder. *Neuropsychopharmacology*. 2015, 40:1448-55. [10.1038/npp.2014.330](https://doi.org/10.1038/npp.2014.330)
24. Serafini G, Adavastro G, Canepa G, et al.: The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. *Int J Mol Sci*. 2018, 19:10.3390/ijms19082410
25. Rosoff DB, Smith GD, Lohoff FW: Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: a multivariable mendelian randomization analysis. *JAMA Psychiatry*. 2021, 78:151-60. [10.1001/jamapsychiatry.2020.3554](https://doi.org/10.1001/jamapsychiatry.2020.3554)
26. Sullivan MD: Depression effects on long-term prescription opioid use, abuse, and addiction . *Clin J Pain*. 2018, 34:878-84. [10.1097/AJP.0000000000000603](https://doi.org/10.1097/AJP.0000000000000603)
27. Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S: Depression and anxiety among chronic pain patients receiving prescription opioids and medical marijuana. *J Affect Disord*. 2017, 218:1-7. [10.1016/j.jad.2017.04.026](https://doi.org/10.1016/j.jad.2017.04.026)